<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537832</url>
  </required_header>
  <id_info>
    <org_study_id>ETX-DS-001</org_study_id>
    <nct_id>NCT04537832</nct_id>
  </id_info>
  <brief_title>Natural History Study of Infants and Children With SCN1A-positive Dravet Syndrome</brief_title>
  <acronym>ENVISION</acronym>
  <official_title>ENVISION: Natural History Study of Infants and Children With SCN1A-positive Dravet Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Encoded Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Encoded Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, 2-year observational study in subjects aged 6 to 60&#xD;
      months (at baseline), inclusive, with SCN1A-positive Dravet Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective natural history study designed to further define the seizure,&#xD;
      neurodevelopmental, motor and behavioral characteristics of SCN1A-positive Dravet Syndrome in&#xD;
      children aged 6 to 60 months (at baseline) with SCN1A mutations. The study will examine these&#xD;
      characteristics over 2 years using standardized assessments and will also explore the impact&#xD;
      of the disease on parents/caregivers and health care resource utilization (HCRU).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">June 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure burden</measure>
    <time_frame>Every 3 months from Baseline through Month 24</time_frame>
    <description>Measured using monthly seizure frequency derived from seizure diaries</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure freedom</measure>
    <time_frame>Within each 6-month interval starting from Baseline through Month 24</time_frame>
    <description>Measured using the proportion of seizure-free days observed between two-time points in the seizure diaries</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motor functioning</measure>
    <time_frame>Baseline, Months 6, 12, 18; and Month 24</time_frame>
    <description>Measured using binary outcomes (achieved vs. not achieved) of 6 motor items adapted from the Bayley Scales of Infant and Toddler Development instrument. Motor milestones include: (1) Sit unassisted for 30 seconds; (2) Walk with assistance; (3) Stand alone; (4) Walk alone; (5) Walk upstairs; and (6) Jump forward</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of anti-epileptic drug</measure>
    <time_frame>Baseline, Months 6, 12, 18 and 24</time_frame>
    <description>Measured using the incidence of anti-epileptic drug usage observed between two time points in the clinical database. Endpoint will be calculated within each 6-month interval from starting from Baseline through Month 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of Ketogenic Diet</measure>
    <time_frame>Baseline, Months 6, 12, 18 and 24</time_frame>
    <description>Measured using the incidence of ketogenic diet usage between two time points. Endpoint will be calculated within each 6-month interval from starting from Baseline through Month 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive functioning</measure>
    <time_frame>Baseline, Months 6, 12, 18 and 24</time_frame>
    <description>Measured using composite scores from 5 domains in the Bayley Scales of Infant and Toddler Development instrument. Domains include: (1) Cognitive; (2) Language; (3) Motor; (4) Social-Emotional; and (5) General Adaptive&#xD;
Composite scores are normalized to a mean and SD of 100 and 15, respectively (range is not applicable as the scores are unbounded). Higher scores correspond to better outcomes compared to a normal population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral and social functioning</measure>
    <time_frame>Baseline, Months 3, 9, 15, 21 and 24</time_frame>
    <description>Measured using raw scores from 2 domains in the Brief Infant Toddler Social Emotional Assessment. Domains include: (1) Problem; and (2) Competence&#xD;
Domain raw scores range from 31 to 93 and 11 to 33 for the Problem and Competence domains, respectively. Higher Problem scores correspond to worse outcomes. Higher Competence scores correspond to better outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Baseline through Month 24</time_frame>
    <description>Measured using the incidence of adverse events and serious adverse events (broken down by preferred term) observed between two time points during the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline through Month 24</time_frame>
    <description>Measured using the incidence of death observed by a given time point during the study</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dravet Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Subjects from 6 through 60 months of age (at baseline) who have SCN1A+ Dravet Syndrome. Clinical, neurocognitive, laboratory, the burden of disease, and health care resource utilization will be assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No Intervention</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children aged 6 to 60 months with SCN1A-positive Dravet Syndrome.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed SCN1A mutation.&#xD;
&#xD;
          -  Normal development prior to onset of first seizure as defined by the Centers for&#xD;
             Disease -Control and Prevention (CDC 2019).&#xD;
&#xD;
          -  Onset of seizures between age 3 and 15 months, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Copy number variant of SCN1A, including SCN1A microdeletion, if affecting other genes.&#xD;
&#xD;
          -  SCN1A mutation present on both alleles. Known pathogenic or clinically suspected&#xD;
             mutation in a seizure-associated gene besides SCN1A.&#xD;
&#xD;
          -  Confirmed mutation in a gene besides SCN1A, as determined by an Independent&#xD;
             Adjudication Committee, that is known to increase the severity of the seizure&#xD;
             phenotype.&#xD;
&#xD;
          -  Subject has a known gain-of-function genetic mutation, as defined by functional&#xD;
             studies, including p.Thr226Met.&#xD;
&#xD;
          -  History of notable developmental deficit that was evident prior to seizure onset.&#xD;
&#xD;
          -  Known central nervous system structural abnormality as found on magnetic resonance&#xD;
             imaging or computed tomography scan of brain.&#xD;
&#xD;
          -  Repeated or prolonged (&gt;6 consecutive weeks) exposure to anti-epileptic drugs (AEDs)&#xD;
             that are contraindicated in SCN1A-positive Dravet Syndrome, including sodium channel&#xD;
             blockers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvador Rico, M.D., Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Encoded Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Encoded Patient Advocacy</last_name>
    <phone>+1 (650) 398-4301</phone>
    <email>patientadvocacy@encoded.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Arellano-Garcia</last_name>
      <email>margarcia@chla.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoinette Swanson</last_name>
      <phone>415-502-1921</phone>
      <email>Antoinette.Swanson@UCSF.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galen Resler</last_name>
      <phone>720-777-0738</phone>
      <email>Galen.resler@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Knupp, MD</last_name>
      <phone>720-777-6895</phone>
      <email>Kelly.knupp@childrenscolorado.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leisa Tamayo Nenninger</last_name>
      <email>Leisa.TamayoNenninger@nicklaushealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasim Alexander</last_name>
      <email>nasalexander@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northeast Regional Epilepsy Group</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Sica</last_name>
      <email>VSica@epilepsygroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abigail Wexner Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Eldred</last_name>
      <phone>614-722-2607</phone>
      <email>Sara.eldred@nationwidechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Dyar</last_name>
      <phone>503-494-8216</phone>
      <email>dyar@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi Risbud</last_name>
      <phone>215-590-3057</phone>
      <email>RISBUDR@chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farimah Salami, PhD, MS</last_name>
      <email>farimah.salami@lebonheur.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Grado, R.N.</last_name>
      <email>Dianna.Grado@cookchildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicare Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Brown</last_name>
      <phone>253-403-9350</phone>
      <email>amber.brown2@multicare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital - Melbourne Brain Centre</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greesha Zacharia</last_name>
      <phone>+61 3 9035 7361</phone>
      <email>greesha.zacharia@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roser Ribosa-Nogu√©</last_name>
      <phone>+34 93 5537075</phone>
      <email>rribosa@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Andreas Brunklaus</last_name>
      <email>andreas.brunklaus@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe myoclonic epilepsy</keyword>
  <keyword>epilepsy</keyword>
  <keyword>severe myoclonic epilepsy of infancy</keyword>
  <keyword>SMEI</keyword>
  <keyword>SCN1A related seizure disorder</keyword>
  <keyword>epileptic encephalopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Plan is undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

